Should I Try Peptides? Part 2
Welcome back! This is Part 2 of my Should I Take Peptides? series, where we’re taking a closer look at peptides and what you should know before considering them for your health.
In Part 1, we looked at what peptides are, why they’ve become such a popular topic, and some of the reasons you may be hearing so much about them right now. In this post, we’re continuing the conversation by looking at an important distinction:
Not all peptides are the same.
Some are well-studied medications with substantial human research behind them. Others are still being researched, with evidence that may come primarily from laboratory or animal studies, rather than clinical trials in humans. In these cases, we may have promising early findings, but much less information about how well they work, who they may benefit, and their long-term safety.
If you’re considering peptides for your own health, understanding what kind of research exists is an important place to start.
Remember:
Most peptides attach to receptors on the outside of your cells and act like messengers, telling your cells what to do.
Some peptides can also influence which genes are turned on or off (epigenetics), without changing the underlying DNA code.
Certain genetic variants may influence how a peptide affects you and the risks associated with its use.
FDA-Approved Peptide Medications
Some peptide-based medications have gone through extensive research, clinical trials, regulatory review, and ongoing safety monitoring. GLP-1 receptor agonists, including semaglutide and tirzepatide, are examples of peptide-based medications with substantial human research behind them. These medications mimic hormones involved in appetite regulation, blood sugar control, and metabolism. They are prescribed for specific medical conditions, including type 2 diabetes and, in some cases, weight management.
That doesn’t mean they are right for everyone.
Like any medication, they have potential benefits, risks, side effects, and other considerations that should be discussed with a qualified healthcare professional. The important distinction is that these medications have a much stronger foundation of human research than many of the peptides currently being promoted in wellness, fitness, and longevity spaces.
Research and Wellness Peptides
Many of the peptides gaining attention online are in a very different category. They are often promoted for recovery, injury healing, muscle growth, fat loss, energy, healthy aging, and longevity. And yes, some do have interesting mechanisms and early research that are worth exploring.
Lab and animal studies can help researchers understand how a peptide might work and identify potential benefits. They can also provide important information for future research. But findings in-vitro or an animal model do not necessarily translate to humans.
Human clinical research helps us answer different questions:
Does it actually work?
Who might benefit?
What dose is appropriate?
What side effects can occur?
And what happens with longer-term use?
This doesn’t mean emerging peptides should be dismissed. It means we need to be mindful and aware about where the evidence stands.
Common Peptides You May Hear About
BPC-157
BPC-157 has gained attention for its potential effects on tissue repair, inflammation, healing, and GI health. You may have heard about it in connection with sports injuries, tendon healing, or digestive concerns. The interest is largely based on lab and animal research suggesting that BPC-157 may influence processes involved in blood vessel formation, tissue recovery, and cellular repair. However, human research remains limited.
The early findings are interesting, but we still need more high-quality human research to understand whether BPC-157 is effective, who may benefit, and what the long-term safety considerations might be. A promising mechanism gives us a reason to study something further. It is not the same as knowing that something is safe and effective for long-term use in humans.
TB-500
TB-500 is a synthetic peptide related to thymosin beta-4, a naturally occurring peptide involved in processes such as cell movement, tissue repair, and blood vessel formation. It has become popular in some wellness and athletic communities because of claims related to recovery, healing, and performance. The biology is interesting, but TB-500 itself does not have the same level of human clinical research as approved medications.
Much of the information available comes from lab and animal research, along with anecdotal reports. And this brings us back to an important question:
Do we know enough about long-term use to weigh the potential benefits against the risks?
For many emerging peptides, we simply don’t have that answer yet.
CJC-1295 and Ipamorelin
CJC-1295 and ipamorelin are both used to influence growth hormone signaling. CJC-1295 is designed to increase growth hormone and IGF-1 levels, while ipamorelin is a growth hormone secretagogue that signals the body to release more growth hormone. These are often promoted for muscle growth, recovery, fat loss, energy, body composition, and healthy aging.
Growth hormone plays important roles in metabolism, tissue repair, and maintaining muscle mass. But hormone pathways are complex, and increasing a particular hormone signal doesn’t necessarily produce the outcome we’re hoping for. More is not always better. The effects can also depend on factors such as age, metabolic health, insulin sensitivity, existing hormone levels, and individual biology.
Long-term research on these peptides in healthy adults using them for wellness or anti-aging purposes remains limited.
Why Long-Term Safety Matters
When a new therapy becomes popular and influencers flock to it, it’s natural to focus on what it might help with. But an equally important question is: What do we know about long-term safety?
A peptide may have a fascinating mechanism and early research showing potential benefits. Keep it on your radar? Absolutely. But a biological effect is not the same thing as a proven clinical benefit.
The human body is also incredibly interconnected. Changing one pathway can influence others, sometimes in ways we don’t fully understand at first. Long-term research matters. We want to know whether something appears to work and also how it may affect the body over time.
Your Health History Is Part of the Picture. A VERY big part of it!
A limitation of many online health conversations is that they make it sound as though the same therapy will have the same effect on everyone. It won’t.
Your response to a therapy can be influenced by many factors, including:
Genetics
Health history
Medications
Hormone status
Blood sugar regulation
Nutrient status
Immune function
Lifestyle
For example, a therapy that influences growth hormone pathways may warrant different consideration in someone with insulin resistance than in someone with optimal metabolic health. Or a therapy that affects immune signaling may require additional consideration for someone with autoimmune concerns. And therapies that influence cellular repair pathways may raise different questions for someone with a significant cancer history.
A peptide that may be reasonable for one person may raise very different questions for another. That’s why these decisions are best made by looking at the person, not just the peptide.
Quality and Sourcing Matter, Too
Do you know where the peptides you’re considering come from?
Some peptide therapies are prescribed through licensed healthcare professionals and obtained from pharmacies operating under applicable regulatory standards. Others are purchased online from companies selling products labeled “for research use only.”
I don’t know about you, but I’m very cautious and very curious about what I put into my body.
If a substance is going to be used in the human body, I want to know where it came from, how it was made, and whether it has been tested for purity, contaminants, accurate dosing, and, when appropriate, sterility.
These may not be the first questions that come to mind when you’re considering a new therapy, but they are important ones. Before putting something into your body, you deserve to know as much as possible about what you’re actually getting.
So, Should You Try Peptides?
Peptides are an interesting and rapidly developing area of medicine and research. Some peptide-based medications are well studied and have become valuable medical tools. Others are still being investigated, with much less human research available.
If you’re considering a peptide, here are some questions worth asking:
What does the research actually show?
What kind of research has been done: laboratory, animal, or human clinical research?
Has the peptide been adequately studied in humans?
What do we know about its potential benefits, risks, and long-term safety?
How does it fit with my health history and goals?
Are there other options with more established evidence?
Are there nutritional, lifestyle, metabolic, hormonal, or other factors that deserve attention first?
There is no single answer to the question, “Should I take peptides?”And yes, I thought I would have a more definite answer after all of this research! But just like naturopathic medicine, it’s individual. The answer depends on the particular peptide, the quality of the evidence, and the person considering it.
We live in a world that seems to prioritize speed. We’re constantly looking for the quickest, easiest, most effective way to get where we want to go. And while efficiency certainly has its place, when it comes to your body ~ your vessel for this lifetime ~ I think it’s worth slowing down enough to consider ALL of your options carefully and have those conversations with a trusted healthcare practitioner.
My hope is that this 2-part series gives you a clearer understanding of what you’re hearing about and helps you ask better questions when you encounter the next peptide promising better health, faster recovery, or a longer life. New therapies will continue to emerge, and research will continue to evolve. We can stay curious, look at the evidence, understand what we know and what we don’t, and take the time to decide whether a particular therapy is right for us.
For more evidence-based insights into whole person wellness, subscribe to our newsletter today.
References
Bajaj, H. S., Welch, M., Shah, P., Luna, E., Jaouimaa, F.-Z., Liu, B., Liu, R., Chen, Y., Patel, H., & Bartee, A. (2026). Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): A double-blind, randomised, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(26)00967-0
Ciudin, A., Sapin, H., Fan, L., Dimitriadis, G. K., Zimner-Rapuch, S., Curteis, T., Clark, L. J., Rubinstein, M., & Johansson, E. (2026). Comparison of clinical efficacy and safety of tirzepatide, liraglutide and semaglutide in patients with obesity and without T2D: A bayesian network meta-analysis of randomised controlled trials. Advances in Therapy, 10.1007/s12325-026-03523-5. https://doi.org/10.1007/s12325-026-03523-5
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D, Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/s0140-6736(21)00213-0
Hsieh, M.-J., Liu, H.-T., Wang, C.-N., Huang, H.-Y., Lin, Y., Ko, Y.-S., Wang, J.-S., Chang, V. H.-S., & Pang, J.-H. S. (2016). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine, 95(3), 323–333. https://doi.org/10.1007/s00109-016-1488-y
Janssens, Y., Wynendaele, E., Vanden Berghe, W., & De Spiegeleer, B. (2019). Peptides as epigenetic modulators: Therapeutic implications. Clinical Epigenetics, 11(1), 101. https://doi.org/10.1186/s13148-019-0700-7
Kaitin, K. I., & DiMasi, J. A. (2010). Pharmaceutical innovation in the 21St century: New drug approvals in the first decade, 2000–2009. Clinical Pharmacology & Therapeutics, 89(2), 183–188. https://doi.org/10.1038/clpt.2010.286
Lee, E., & Burgess, K. (2025). Safety of intravenous infusion of BPC157 in humans: A pilot study. Alternative Therapies in Health and Medicine, 31(5), 20–24. https://pubmed.ncbi.nlm.nih.gov/40131143/
Luansritisakul, C., Chiang, M. C., Burns, S. L., & Fonseca, A. C. G. (2026). Peptides in regenerative medicine: A comprehensive review of clinical applications in tissue repair and chronic pain management. Current Pain and Headache Reports, 30(1), 109. https://doi.org/10.1007/s11916-026-01542-z
Mateescu, D.-M., Gavrilescu, D.-M., Constantinescu, F. E., Oancea, C., Ilie, A.-C., Folescu, R., Popa, M.-D., Iurciuc, S., Muresan, C.-O., & Enache, A. (2026). BPC-157 as an investigational peptide therapeutic: Biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics, 18(5), 625. https://doi.org/10.3390/pharmaceutics18050625
Mayfield, C. K., Bolia, I. K., Feingold, C. L., Lin, E. H., Liu, J. N., Rick, G. F., Gamradt, S. C., & Weber, A. E. (2026). Injectable peptide therapy: A primer for orthopaedic and sports medicine physicians. The American Journal of Sports Medicine, 54(1), 223–229. https://doi.org/10.1177/03635465251357593
Mendias, C. L., & Awan, T. M. (2026). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Medicine. https://doi.org/10.1007/s40279-026-02437-0
Pérez López, G. (2025). GLP-1 receptor agonists and GIP/GLP-1 co-agonists in the treatment of obesity in adolescents and the elderly. Medicina Clinica, 165(4), 107122. https://doi.org/10.1016/j.medcli.2025.107122
Rahman, O. F., Lee, S. J., & Seeds, W. A. (2026). Therapeutic peptides in orthopaedics: Applications, challenges, and future directions. JAAOS: Global Research and Reviews, 10(1). https://doi.org/10.5435/jaaosglobal-d-25-00236
Renke, G., & Chinellato, L. (2026). Therapeutic peptides in aesthetic, metabolic and endocrine conditions: Effects, safety, clinical applications, and future perspectives. International Journal of Molecular Sciences, 27(9), 3890. https://doi.org/10.3390/ijms27093890
Tewari, K., Liu, T. P., Im, C., Hamad, C., Petrigliano, F., Cheung, E. C., & Kremen, T. J. (2026). Peptide supplements and their therapeutic applications in sports medicine. The American Journal of Sports Medicine, 3635465261464420. https://doi.org/10.1177/03635465261464420
Vasireddi, N., Hahamyan, H., Salata, M. J., Karns, M., Calcei, J. G., Voos, J. E., & Apostolakos, J. M. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery. https://doi.org/10.1177/15563316251355551
For more evidence-based insights into whole person wellness, subscribe to our newsletter today.
This article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease or medical condition. Health decisions are personal and should be made based on your individual health history, goals, and circumstances. Information shared here is not a substitute for personalized medical advice from a qualified healthcare professional. If you are considering peptide therapy or any new health intervention, discuss your options with a healthcare provider who can help you understand the potential benefits, risks, and considerations specific to you.
